[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Neurology](https://durgical.com/en/neurology/) › [Demyelination and neuroimmunology](https://durgical.com/en/neurology/areas/demyelinating/) › Treating MS: relapses, disease-modifying therapy and symptoms

# Treating MS: relapses, disease-modifying therapy and symptoms

- Concept

MS treatment has three jobs: shorten an attack, prevent the next one and ease daily symptoms. Starting prevention early protects the brain.

Updated Nov 16, 2026

**See it in 3D:** [Optic nerve](https://durgical.com/en/anatomy/optic-nerve/) · [Spinal cord](https://durgical.com/en/anatomy/spinal-cord/) · [Corpus callosum](https://durgical.com/en/anatomy/corpus-callosum/) · [Lateral ventricles](https://durgical.com/en/anatomy/lateral-ventricle/)

## Key points

- Relapse: high-dose [corticosteroids](https://durgical.com/en/pharmacology/classes/corticosteroids/) shorten the attack but do not change long-term disability; plasma exchange for a severe relapse that does not respond.
- Exclude infection before calling it a relapse: fever, urinary infection and heat bring back old symptoms (pseudo-relapse).
- DMTs reduce relapses and new MRI lesions; start early, because most of the benefit comes in the inflammatory phase.
- Higher-efficacy agents ([natalizumab](https://durgical.com/en/pharmacology/natalizumab/), anti-CD20 [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/), [alemtuzumab](https://durgical.com/en/pharmacology/alemtuzumab/), [cladribine](https://durgical.com/en/pharmacology/cladribine/), S1P modulators) carry more infection and drug-specific risks; natalizumab carries PML risk linked to [JC virus](https://durgical.com/en/microbiology/jc-polyomavirus/) antibodies.
- Pregnancy must be planned: [teriflunomide](https://durgical.com/en/pharmacology/teriflunomide/) and cladribine are teratogenic; relapses usually fall in pregnancy and rise after delivery; stopping natalizumab or S1P modulators can cause rebound.
- Progressive MS: anti-CD20 therapy ([ocrelizumab](https://durgical.com/en/pharmacology/ocrelizumab/)) for primary progressive and [siponimod](https://durgical.com/en/pharmacology/siponimod/) for active secondary progressive disease; rehabilitation and symptoms are central.

On this page

- The basics Key points
- What it is
- How to think about it
- Key points
- Step by step
- DMT classes: what you gain and what you risk
- In practice
- Next step
- Common traps
- Elsewhere in DurgiPedia

- Study Test yourself

- Connections Connections

## What it is

Treatment of [multiple sclerosis](https://durgical.com/en/conditions/multiple-sclerosis/) (MS) works on three levels. A relapse that impairs function is treated with a short course of high-dose corticosteroids, and plasma exchange if it is severe and does not respond; this speeds recovery but does not change long-term disability. Disease-modifying therapies (DMTs) reduce new relapses and new MRI lesions by acting on immune cells: injectable modulators, oral agents and monoclonal antibodies, chosen by balancing efficacy against risks such as infection, progressive multifocal leukoencephalopathy (PML), effects in pregnancy and monitoring burden. Progressive MS responds much less, with a few agents for active or early progressive disease. Symptom treatment and rehabilitation address spasticity, bladder, fatigue, pain, mood and walking.

## How to think about it

Think of MS as fires lit by immune cells crossing into the brain and cord. Corticosteroids are the firefighters for today's fire: they put it out faster but do nothing about tomorrow's. Disease-modifying drugs are fire prevention: the stronger ones keep more immune cells out or remove them, but the more of the immune system you hold back, the more the body is exposed to infections it normally controls. Once the house smoulders from within, with slow progression and little new inflammation, prevention helps much less, so the time to act is early.

## Key points

- Injectable modulators ([interferon beta](https://durgical.com/en/pharmacology/interferon-beta/), [glatiramer acetate](https://durgical.com/en/pharmacology/glatiramer-acetate/)): long safety record, moderate efficacy; interferon can cause flu-like symptoms, depression and [liver](https://durgical.com/en/anatomy/liver/) changes.
- Oral agents: teriflunomide (liver, teratogenic), [dimethyl fumarate](https://durgical.com/en/pharmacology/dimethyl-fumarate/) (flushing, gut symptoms, lymphopenia with rare PML), S1P modulators [fingolimod](https://durgical.com/en/pharmacology/fingolimod/), siponimod, [ozanimod](https://durgical.com/en/pharmacology/ozanimod/) (first-dose slow heart rate, macular oedema, herpes infections).
- Natalizumab blocks lymphocyte entry into the brain; PML risk rises with JC virus antibodies, longer treatment and prior immunosuppression.
- Anti-CD20 antibodies (ocrelizumab, ofatumumab; [rituximab](https://durgical.com/en/pharmacology/rituximab/) used off-label) deplete B cells: infusion reactions, infections, falling immunoglobulins, hepatitis B reactivation.
- Alemtuzumab and cladribine are given in short courses that reset lymphocytes; alemtuzumab causes later autoimmunity (thyroid, platelets, kidney).
- Before any immunosuppressive DMT: screen hepatitis B and C, HIV, [latent tuberculosis](https://durgical.com/en/conditions/latent-tuberculosis-infection/) (relevant in Colombia) and [varicella](https://durgical.com/en/conditions/varicella/) immunity, and give needed vaccines first (no live vaccines once immunosuppressed).
- Two strategies: escalation (moderate agent first, switch on breakthrough) or early high efficacy for aggressive disease (frequent relapses, many or spinal lesions, poor recovery).
- Symptoms: spasticity (physiotherapy, [baclofen](https://durgical.com/en/pharmacology/baclofen/), [tizanidine](https://durgical.com/en/pharmacology/tizanidine/)), bladder ([antimuscarinics](https://durgical.com/en/pharmacology/classes/antimuscarinics/), intermittent catheterisation), fatigue, [neuropathic pain](https://durgical.com/en/neurology/neuropathic-pain-syndromes-the-lesion-decides-the-treatment/), depression, walking speed ([fampridine](https://durgical.com/en/pharmacology/fampridine/)).

## Step by step

- New or worse symptoms for more than a day: check temperature, urine and recent infection first.
- A true relapse that limits function (vision, walking, hand use) is treated with corticosteroids; a mild sensory relapse may need none.
- Severe relapse not improving: plasma exchange, and reconsider NMOSD or MOGAD.
- Confirmed MS: start a DMT early after infection screening and a talk about pregnancy plans.
- Choose by disease activity and the person: pregnancy plans, other illnesses, JC virus status, monitoring capacity and access.
- Monitor with clinical review, MRI and the blood tests each drug needs.
- Breakthrough (new relapse, new lesions or progression despite adherence): switch class, with a planned bridge to avoid rebound.
- Throughout: rehabilitation, symptom treatment, mood, work and family planning.

## DMT classes: what you gain and what you risk

| Class | Examples | Efficacy | Main risks | Pregnancy planning |
| --- | --- | --- | --- | --- |
| Injectable modulators | Interferon beta, glatiramer acetate | Moderate | Flu-like symptoms, injection reactions, liver (interferon) | Among the options most often used around conception, on specialist advice |
| Daily oral agents | Teriflunomide, dimethyl fumarate | Moderate | Liver, hair thinning; flushing, lymphopenia, rare PML | Teriflunomide is teratogenic and needs accelerated elimination |
| S1P receptor modulators | Fingolimod, siponimod, ozanimod | Moderate to high | Slow heart rate at first dose, macular oedema, herpes infections | Stop before conception with a plan; rebound possible |
| Anti-integrin | Natalizumab | High | PML (JC virus), infections | Specialist plan; rebound if stopped abruptly |
| Anti-CD20 | Ocrelizumab, ofatumumab, rituximab | High | Infusion reactions, infections, low immunoglobulins, hepatitis B reactivation | Time the last infusion before conception |
| Immune reconstitution | Alemtuzumab, cladribine | High | Later autoimmunity (alemtuzumab), infections, lymphopenia | Waiting period before conception; cladribine teratogenic |

## In practice

- Giving steroids for a urinary infection mistaken for a relapse worsens the infection and wastes the course.
- On natalizumab, new cognitive, behavioural, language or visual change over weeks suggests PML: stop the drug, request MRI and CSF JC virus PCR.
- Screen latent [tuberculosis](https://durgical.com/en/conditions/tuberculosis/) and hepatitis B before lymphocyte-depleting drugs; reactivation is a preventable harm.
- Relapse risk rises in the months after delivery; plan when to restart the DMT and whether it is compatible with [breastfeeding](https://durgical.com/en/nursing/breastfeeding-support-latch-positions-and-common-problems/).

## Next step

- Before treating a relapse: temperature, [urinalysis](https://durgical.com/en/biochemistry/topics/urinalysis/) and an infection screen; MRI if the diagnosis or activity is uncertain.
- Before a DMT: hepatitis B and C, HIV, latent tuberculosis test, varicella serology, blood count, liver tests, pregnancy test; JC virus antibodies before natalizumab.
- On treatment: blood count and liver tests as each drug requires, lymphocytes on fumarates and S1P modulators, immunoglobulins on anti-CD20, regular blood, urine and thyroid tests for years after alemtuzumab.
- Eye examination for macular oedema after starting an S1P modulator; heart rhythm monitoring at the first dose of fingolimod.
- Brain MRI at least yearly, and sooner after a switch, to detect silent activity.

## Common traps

- **Steroids for a relapse prevent future disability**: they speed recovery from that attack but do not change the long-term course, which is the job of the DMT.
- **Every worsening is a relapse**: fever, infection, heat and fatigue bring back old deficits (pseudo-relapse), so treat the trigger first.
- **The strongest drug is always best**: higher efficacy comes with more infection and drug-specific risks, so the choice weighs disease activity against the person's risks and plans.
- **Stopping a DMT is harmless once the patient is stable**: stopping natalizumab or S1P modulators can cause severe rebound activity, so switches need a planned bridge.
- **DMTs work equally well in progressive MS**: they act on inflammation, so the benefit is small when progression occurs without relapses or new lesions.

## Test yourself

Think of the answer, then tap the question to see it.

## A woman with MS has had worse leg stiffness for two days, with fever and painful urination. What do you do before giving corticosteroids, and why?

Treat the urinary infection and reassess: fever brings back old deficits (pseudo-relapse). Corticosteroids are for a true relapse lasting more than a day without infection.

## A patient on natalizumab for years develops word-finding difficulty and right arm clumsiness over weeks. What do you suspect and what next?

PML from JC virus: stop natalizumab, request MRI and CSF JC virus PCR, and involve the MS team; JC antibodies and long treatment raise the risk.

## Why might a neurologist start a high-efficacy agent first in a young man with frequent relapses and spinal cord lesions?

Aggressive inflammatory disease predicts disability, and most of the benefit of DMTs comes early; in his case the gain outweighs the higher infection risk, after screening.

## A woman taking teriflunomide wants to become pregnant. What is the issue and what is done?

Teriflunomide is teratogenic and stays in the body for months; it needs an accelerated elimination procedure and confirmed low blood levels before conception, planned with the neurologist.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/neurology/treating-ms-relapses-disease-modifying-therapy-and-symptoms/)

## Elsewhere in DurgiPedia

- [Multiple sclerosis: the plaque](https://durgical.com/en/general-pathology/multiple-sclerosis-the-plaque/)
- [Brain MRI: when it beats CT](https://durgical.com/en/radiology/brain-mri-when-it-beats-ct/)
- [Spine MRI: cord compression, disc and infection](https://durgical.com/en/radiology/spine-mri-cord-compression-disc-and-infection/)
- [Shared decision-making](https://durgical.com/en/behavioral-science/shared-decision-making/)
- [Adherence: what it is and why it fails](https://durgical.com/en/behavioral-science/adherence-what-it-is-and-why-it-fails/)

## Connections

## See it in 3D 4

The structures of Durgical's 3D anatomy where it is found.

- [Optic nerve](https://durgical.com/en/anatomy/optic-nerve/)
- [Spinal cord](https://durgical.com/en/anatomy/spinal-cord/)
- [Corpus callosum](https://durgical.com/en/anatomy/corpus-callosum/)
- [Lateral ventricles](https://durgical.com/en/anatomy/lateral-ventricle/)

## Related 6

- [Multiple sclerosis: different places, different times](https://durgical.com/en/neurology/multiple-sclerosis-different-places-different-times/)
- [NMOSD and MOGAD: when it is not MS](https://durgical.com/en/neurology/nmosd-and-mogad-when-it-is-not-ms/)
- [Acute disseminated encephalomyelitis after infection or vaccination](https://durgical.com/en/neurology/acute-disseminated-encephalomyelitis-after-infection-or-vaccination/)
- [When the MRI shows no compression: myelitis, infarct, B12, HTLV-1](https://durgical.com/en/neurology/when-the-mri-shows-no-compression-myelitis-infarct-b12-htlv-1/)
- [Myelopathy: find the level, then the tracts](https://durgical.com/en/neurology/myelopathy-find-the-level-then-the-tracts/)
- [HIV and the nervous system, by CD4 count](https://durgical.com/en/neurology/hiv-and-the-nervous-system-by-cd4-count/)

## Related conditions 6

- [Multiple sclerosis](https://durgical.com/en/conditions/multiple-sclerosis/)
- [Optic neuritis](https://durgical.com/en/conditions/optic-neuritis/)
- [Transverse myelitis](https://durgical.com/en/conditions/transverse-myelitis/)
- [Neuromyelitis optica spectrum disorder](https://durgical.com/en/conditions/neuromyelitis-optica-spectrum-disorder/)
- [Urinary tract infection (acute cystitis)](https://durgical.com/en/conditions/urinary-tract-infection/)
- [Tuberculosis](https://durgical.com/en/conditions/tuberculosis/)

## Microorganisms 1

- [JC polyomavirus](https://durgical.com/en/microbiology/jc-polyomavirus/)

## In Pharmacology 19

- [Multiple sclerosis disease-modifying therapies](https://durgical.com/en/pharmacology/classes/multiple-sclerosis-disease-modifying-therapies/)
- [Corticosteroids (glucocorticoids)](https://durgical.com/en/pharmacology/classes/corticosteroids/)
- [Methylprednisolone](https://durgical.com/en/pharmacology/methylprednisolone/)
- [Interferon beta](https://durgical.com/en/pharmacology/interferon-beta/)
- [Glatiramer acetate](https://durgical.com/en/pharmacology/glatiramer-acetate/)
- [Teriflunomide](https://durgical.com/en/pharmacology/teriflunomide/)
- [Dimethyl fumarate](https://durgical.com/en/pharmacology/dimethyl-fumarate/)
- [Fingolimod](https://durgical.com/en/pharmacology/fingolimod/)
- [Siponimod](https://durgical.com/en/pharmacology/siponimod/)
- [Ozanimod](https://durgical.com/en/pharmacology/ozanimod/)
- [Natalizumab](https://durgical.com/en/pharmacology/natalizumab/)
- [Ocrelizumab](https://durgical.com/en/pharmacology/ocrelizumab/)

## See all 19

- [Rituximab](https://durgical.com/en/pharmacology/rituximab/)
- [Alemtuzumab](https://durgical.com/en/pharmacology/alemtuzumab/)
- [Cladribine](https://durgical.com/en/pharmacology/cladribine/)
- [Baclofen](https://durgical.com/en/pharmacology/baclofen/)
- [Tizanidine](https://durgical.com/en/pharmacology/tizanidine/)
- [Fampridine](https://durgical.com/en/pharmacology/fampridine/)
- [Oxybutynin](https://durgical.com/en/pharmacology/oxybutynin/)

[← All of neurology](https://durgical.com/en/neurology/)

Educational content; it does not replace supervised training, your institution's protocols or a medical assessment. It contains no doses. For signs of stroke (face drooping, arm weakness, speech trouble), a prolonged seizure or fever with a stiff neck, call the emergency number (123 in Colombia) or go to the nearest emergency department.

Sources: [Multiple Sclerosis](https://www.ncbi.nlm.nih.gov/books/NBK499849/) (StatPearls (NCBI Bookshelf), 2024); [Multiple sclerosis (Medical Encyclopedia)](https://medlineplus.gov/ency/article/000737.htm) (MedlinePlus (U.S. National Library of Medicine), 2025); [Progressive multifocal leukoencephalopathy](https://medlineplus.gov/ency/article/000674.htm) (MedlinePlus (U.S. National Library of Medicine), 2025); [Alemtuzumab Injection (Multiple Sclerosis): MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a619012.html) (MedlinePlus (U.S. National Library of Medicine), 2025).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/neurology/treating-ms-relapses-disease-modifying-therapy-and-symptoms/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/neurology/treating-ms-relapses-disease-modifying-therapy-and-symptoms/
